Biohaven Ltd (BHVN)

Mar 27, 2025, 7:40 AM EDT - 7 days ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE DNLI GPCR INSM MRK SWTX

Mar 20, 2025, 10:00 AM EDT - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bronstein, Gewirtz & Grossman, LLC (BHVN) and Encourages Stockholders to Learn More About the Investigation

Mar 19, 2025, 10:00 AM EDT - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Shareholders to Learn More About the Investigation

Mar 18, 2025, 10:00 AM EDT - 16 days ago

Biohaven Ltd. (BHVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 17, 2025, 1:30 PM EDT - 17 days ago

Biohaven Ltd. Being Investigated on Behalf of Biohaven Ltd.

Mar 17, 2025, 10:00 AM EDT - 17 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Shareholders to Inquire about Securities Investigation

Mar 16, 2025, 10:00 AM EDT - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Shareholders to Connect

Mar 14, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Investors to Connect

Mar 13, 2025, 10:00 AM EDT - 21 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Stockholders to Inquire about Securities Investigation

Mar 12, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Investors to Learn More About the Investigation

Mar 11, 2025, 10:00 AM EDT - 23 days ago

Biohaven Ltd. (BHVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 9, 2025, 10:00 AM EDT - 25 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Stockholders to Learn More About the Investigation

Mar 7, 2025, 10:00 AM EST - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Investors to Inquire about Securities Investigation

Mar 6, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biohaven Ltd. (BHVN) And Encourages Investors to Reach Out

Mar 5, 2025, 10:30 AM EST - 4 weeks ago

Did Biohaven Ltd. Mislead Investors?

Mar 5, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biohaven Ltd. (BHVN) And Encourages Stockholders to Reach Out

Mar 4, 2025, 12:00 PM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Stockholders to Connect

Mar 3, 2025, 1:09 PM EST - 4 weeks ago

Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy

Mar 3, 2025, 7:31 AM EST - 4 weeks ago

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

Mar 3, 2025, 7:30 AM EST - 4 weeks ago

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 5:14 AM EST - 4 weeks ago

Biohaven's Exciting Year Of Catalysts

Feb 11, 2025, 5:47 PM EST - 7 weeks ago

Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck

Feb 11, 2025, 7:30 AM EST - 7 weeks ago

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Jan 13, 2025, 11:15 AM EST - 2 months ago

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy

Jan 7, 2025, 5:54 PM EST - 3 months ago

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 2:23 PM EST - 3 months ago

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

Dec 16, 2024, 7:30 AM EST - 3 months ago

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

Dec 6, 2024, 7:30 AM EST - 4 months ago

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

Nov 29, 2024, 5:30 AM EST - 4 months ago

Biohaven's Revenue Path: SCA And Obesity Therapies

Nov 25, 2024, 8:32 AM EST - 4 months ago

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

SAVA

Nov 25, 2024, 7:45 AM EST - 4 months ago

Biohaven's spinal muscular atrophy drug fails to meet main goal in study

Nov 25, 2024, 7:30 AM EST - 4 months ago

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

Nov 12, 2024, 4:05 PM EST - 5 months ago

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

Oct 2, 2024, 4:05 PM EDT - 6 months ago

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 1, 2024, 6:00 AM EDT - 6 months ago

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

Sep 30, 2024, 4:05 PM EDT - 6 months ago

Biohaven Announces Proposed Public Offering of Common Shares

Sep 30, 2024, 7:30 AM EDT - 6 months ago

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine